TD Waterhouse Canada’s Adaptimmune Therapeutics ADAP Stock Holding History

TD Waterhouse Canada’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14	Closed	–	–	2308
2025 Q4	$0	Hold	14	–	–	﹤0.01%	2041
2025 Q3	$2	Hold	14	–	–	﹤0.01%	2061
2025 Q2	$3	Hold	14	–	–	﹤0.01%	1986
2025 Q1	$4	Hold	14	–	–	﹤0.01%	1938
2024 Q4	$8	Hold	14	–	–	﹤0.01%	1948
2024 Q3	$13	Buy	+14	New	+$16	﹤0.01%	1880

Other funds holding ADAP

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

TD Waterhouse Canada's ADAP Position: Q1 2026 in Review

TD Waterhouse Canada sold out of Adaptimmune Therapeutics (ADAP) in Q1 2026, closing a stake of 14 shares.

TD Waterhouse Canada first reported a position in ADAP in Q3 2024 and held it in 6 quarters. The position peaked at $13 in Q3 2024. 1 fund tracked by Wall St. Rank holds ADAP as of Q1 2026.

TD Waterhouse Canada reported no remaining Adaptimmune Therapeutics position as of Q1 2026 after selling out during the quarter.
TD Waterhouse Canada sold 14 Adaptimmune Therapeutics shares in Q1 2026.
TD Waterhouse Canada first reported a position in Adaptimmune Therapeutics in Q3 2024 and held it in 6 quarters.
TD Waterhouse Canada's Adaptimmune Therapeutics position peaked at $13 in Q3 2024.
1 fund tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2026.

Based on TD Waterhouse Canada's 13F filing for Q1 2026, filed 12 May 2026.